Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03433001 · OUTCOME

Relative Dose Intensity (RDI)

A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone · Source last updated 2023-12-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
Percent
Interval / dispersion
Standard Deviation
Time frame
Up to 36 months as a maximum

What was measured

RDI is defined as 100\*(Total amount of dose taken)/(Total prescribed dose of treated cycles), where total prescribed dose equals \[dose prescribed at enrollment\* number of prescribed doses per cycle\* the number of treated cycles\].

Analysis population: Full Analysis Set, defined as all participants who were enrolled into the study and who receive at least one dose of ixazomib.

Groups in this outcome

Ixazomib + Lenalidomide + Dexamethasone

Participants took ixazomib, lenalidomide, and dexamethasone under conditions of standard medical care in this study. The dosage and administration of ixazomib, lenalidomide, and dexamethasone were not defined by the protocol but according to the package insert of each drug.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Ixazomib + Lenalidomide + Dexamethasone295

Reported measurements

Ixazomib
Values in Percent · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Ixazomib + Lenalidomide + Dexamethasone66.4921.054Not reportedNot reportedNot reported
Lenalidomide
Values in Percent · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Ixazomib + Lenalidomide + Dexamethasone44.7222.815Not reportedNot reportedNot reported
Dexamethasone
Values in Percent · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Ixazomib + Lenalidomide + Dexamethasone41.0726.571Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        21.054
        value
        66.49
    title
    Ixazomib
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        22.815
        value
        44.72
    title
    Lenalidomide
  3. categories
    1. measurements
      1. group Id
        OG000
        spread
        26.571
        value
        41.07
    title
    Dexamethasone
denoms
  1. counts
    1. group Id
      OG000
      value
      295
    units
    Participants
description
RDI is defined as 100\*(Total amount of dose taken)/(Total prescribed dose of treated cycles), where total prescribed dose equals \[dose prescribed at enrollment\* number of prescribed doses per cycle\* the number of treated cycles\].
dispersion Type
Standard Deviation
groups
  1. description
    Participants took ixazomib, lenalidomide, and dexamethasone under conditions of standard medical care in this study. The dosage and administration of ixazomib, lenalidomide, and dexamethasone were not defined by the protocol but according to the package insert of each drug.
    id
    OG000
    title
    Ixazomib + Lenalidomide + Dexamethasone
param Type
MEAN
population Description
Full Analysis Set, defined as all participants who were enrolled into the study and who receive at least one dose of ixazomib.
reporting Status
POSTED
time Frame
Up to 36 months as a maximum
title
Relative Dose Intensity (RDI)
type
SECONDARY
unit Of Measure
Percent

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice